Ken Griffin Durect Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.43 - $5.9 $299,955 - $4.12 Million	-697,570 Reduced 91.65%	63,544 $37,000
Q2 2022 Aug 15, 2022	BUY	$0.38 - $0.64 $245,713 - $413,833	646,615 Added 564.73%	761,114 $364,000
Q1 2022 May 16, 2022	SELL	$0.55 - $0.98 $2,554 - $4,552	-4,645 Reduced 3.9%	114,499 $77,000
Q4 2021 Feb 14, 2022	BUY	$0.9 - $1.31 $74,997 - $109,163	83,331 Added 232.68%	119,144 $117,000
Q3 2021 Nov 15, 2021	SELL	$1.21 - $1.61 $197,998 - $263,452	-163,635 Reduced 82.04%	35,813 $46,000
Q2 2021 Aug 16, 2021	BUY	$1.6 - $2.02 $175,777 - $221,919	109,861 Added 122.63%	199,448 $325,000
Q1 2021 May 17, 2021	BUY	$1.86 - $2.87 $74,284 - $114,622	39,938 Added 80.44%	89,587 $177,000
Q4 2020 Feb 16, 2021	SELL	$1.65 - $2.43 $73,421 - $108,130	-44,498 Reduced 47.26%	49,649 $103,000
Q1 2020 May 15, 2020	SELL	$0.97 - $2.85 $88,617 - $260,370	-91,358 Reduced 49.25%	94,147 $146,000
Q4 2019 Feb 14, 2020	BUY	$1.69 - $3.8 $156,147 - $351,101	92,395 Added 99.23%	185,505 $705,000
Q3 2019 Nov 14, 2019	BUY	$0.61 - $2.21 $30,782 - $111,523	50,463 Added 118.33%	93,110 $171,000
Q4 2018 Feb 14, 2019	SELL	$0.48 - $1.1 $14,515 - $33,264	-30,240 Reduced 41.49%	42,647 $20,000
Q3 2018 Nov 13, 2018	BUY	$1.06 - $1.69 $40,907 - $65,220	38,592 Added 112.53%	72,887 $0
Q2 2018 Aug 10, 2018	BUY	$1.56 - $2.51 $16,894 - $27,183	10,830 Added 46.15%	34,295 $0
Q1 2018 May 11, 2018	SELL	$0.91 - $2.24 $68,188 - $167,847	-74,932 Reduced 76.15%	23,465 $50,000
Q4 2017 Feb 09, 2018	BUY	$0.78 - $2.1 $46,573 - $125,388	59,709 Added 154.33%	98,397 $90,000
Q3 2017 Nov 09, 2017	BUY	$1.55 - $1.82 $59,966 - $70,412	38,688	38,688 $68,000

Others Institutions Holding DRRX

# of Institutions

Shares Held

593K

Call Options Held

Put Options Held

View Full List

About DURECT CORP

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $171M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

More about DRRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account